COVID-19 patients showed significantly increased levels of CRP+ EVs, which represented 43.0 [19.0–57.0] % of the total count of PS-exposing EVs, vs. 4.0 [3.0–7.5] % in healthy controls. Here, CRP is linked to COVID-19.